揚(yáng)帆出海，向海圖強(qiáng)。當(dāng)中國(guó)醫(yī)藥產(chǎn)品走向更廣闊的全球市場(chǎng)，好品質(zhì)的標(biāo)尺如何劃定？揚(yáng)子江藥業(yè)集團(tuán)（以下簡(jiǎn)稱揚(yáng)子江）正用中國(guó)質(zhì)量的硬核實(shí)力給出答案——成為全球公眾健康的可靠選項(xiàng)。

2025年，這家發(fā)源于長(zhǎng)江之濱的民族藥企，實(shí)現(xiàn)歷史性突破——成為首家通過(guò)世界三大質(zhì)量獎(jiǎng)之一“EFQM全球獎(jiǎng)”RbE現(xiàn)場(chǎng)評(píng)審“七星”認(rèn)證的中國(guó)藥企。質(zhì)量實(shí)力的背后，是一套以“為父母制藥 為親人制藥”的質(zhì)量文化為內(nèi)核，貫通頂層設(shè)計(jì)與生產(chǎn)一線的全鏈條管理體系。揚(yáng)子江將EFQM模型、“大質(zhì)量”理念深度嵌入從原料種植、生產(chǎn)制造到流通服務(wù)的全過(guò)程，牢牢把握對(duì)“好”質(zhì)量的主動(dòng)權(quán)。旗下多個(gè)車間和品種接連通過(guò)歐盟EMA、美國(guó)FDA、日本PMDA等國(guó)際權(quán)威認(rèn)證。今年4月，喜訊再次傳來(lái)，揚(yáng)子江一次性通過(guò)烏干達(dá)GMP核查，這也是其在非洲市場(chǎng)的首個(gè)官方現(xiàn)場(chǎng)認(rèn)證，國(guó)際化戰(zhàn)略在非洲大陸落下關(guān)鍵一子。

憑借數(shù)十年的質(zhì)量堅(jiān)守、體系建設(shè)、品牌打造與創(chuàng)新突破，揚(yáng)子江的質(zhì)量建設(shè)成果獲得全球市場(chǎng)的信任。2025年全年，揚(yáng)子江國(guó)際化營(yíng)收同比增長(zhǎng)超4倍，合作伙伴數(shù)量增長(zhǎng)逾2倍，百余品種出口至40多個(gè)國(guó)家和地區(qū)，覆蓋歐洲、北美、亞太等主流市場(chǎng)，持續(xù)書寫中國(guó)醫(yī)藥質(zhì)量的時(shí)代答卷。

獲得國(guó)際認(rèn)可，只是起點(diǎn)。參與全球質(zhì)量標(biāo)準(zhǔn)建設(shè)，是更深層的突破。揚(yáng)子江參與起草的5項(xiàng)中藥材質(zhì)量標(biāo)準(zhǔn)被正式錄入《歐洲藥典》；位于中國(guó)福建福鼎的梔子基地、內(nèi)蒙古土默特的有機(jī)黃芪基地，均通過(guò)世界衛(wèi)生組織認(rèn)可的GACP認(rèn)證。從藥材標(biāo)準(zhǔn)到種植源頭，中國(guó)醫(yī)藥質(zhì)量正與全球規(guī)則展開全面接軌。

“讓‘好’能力走出去，是更高層次的國(guó)際化?！睋P(yáng)子江相關(guān)負(fù)責(zé)人表示。在烏干達(dá)，揚(yáng)子江團(tuán)隊(duì)正為當(dāng)?shù)厮幤筇峁┕I(yè)生產(chǎn)技術(shù)支持，助力提升當(dāng)?shù)蒯t(yī)藥制造產(chǎn)業(yè)水平；在老撾，企業(yè)規(guī)劃建設(shè)胖大海種植基地，既從源頭保障原料品質(zhì)，也帶動(dòng)當(dāng)?shù)禺a(chǎn)業(yè)升級(jí)。目前，揚(yáng)子江的多項(xiàng)工業(yè)技術(shù)服務(wù)正在全球同步推進(jìn)，實(shí)現(xiàn)從產(chǎn)品輸出向質(zhì)量管理體系與技術(shù)輸出的延伸，筑強(qiáng)全球生態(tài)“共贏鏈”。

2026年是揚(yáng)子江“國(guó)際化元年”，是向全球市場(chǎng)縱深布局、實(shí)現(xiàn)突破性發(fā)展的新起點(diǎn)。企業(yè)以質(zhì)量為錨、向海而行的成長(zhǎng)軌跡，是中國(guó)民族工業(yè)向上攀登、與世界共進(jìn)的生動(dòng)縮影——正如其多年質(zhì)量實(shí)踐所印證的：真正的好質(zhì)量，既要自身過(guò)硬，更要成就他人、惠及世界。

媒體報(bào)道

China’s Yangtze River Pharmaceutical Group Expands Global Footprint as Quality Drives Growth

In 2025, Yangtze River Pharmaceutical Group (YRPG) made significant progress in both global growth and quality initiatives. The company’s international revenue increased more than fourfold year over year, while the number of its global partners more than doubled. Over 100 products were exported to more than 40 countries and regions across Europe, North America, and the Asia-Pacific, further broadening the company’s presence.

This growth is supported by sustained international recognition of YRPG’s quality system. In 2025, the company became the first Chinese pharmaceutical firm to receive Seven-Star certification under the EFQM Recognised by Excellence (RbE) framework, a globally used management assessment model from the European Foundation for Quality Management. Its quality framework is built on a philosophy of “Making medicines by considering customers as our parents and loved ones,” embedded across the full value chain and combining the EFQM model with an integrated, end-to-end quality management approach from raw materials to distribution.

YRPG’s quality system continues to be validated by global regulators, with facilities and products certified by the EMA, FDA, and PMDA. In April, the company also passed a GMP inspection in Uganda on its first attempt, marking its first on-site certification in Africa and supporting further expansion in the region.

Beyond international recognition, YRPG is actively contributing to the development of global quality standards. Five traditional Chinese medicinal material quality standards co-developed by the company have been included in the European Pharmacopoeia. Its Gardenia cultivation base in Fuding, Fujian Province, and its organic Astragalus base in Tumed Right Banner, Inner Mongolia, have both obtained WHO-recognized GACP certification. From raw materials to cultivation, YRPG continues to align its quality system with international benchmarks.

In Uganda, YRPG provides production and technical support to local manufacturers. In Laos, it plans to establish a Pangdahai cultivation base to secure raw material quality and support local industry development. The company is also extending its industrial technical services globally, moving beyond product supply to include quality management systems and technology transfer, contributing to a more resilient global partnership ecosystem.

2026 marks a new phase in YRPG’s global roadmap, signaling a deeper push into international markets and a shift toward sustained, multi-market operations. As pharmaceutical markets evolve, quality, compliance, and supply reliability remain central. Anchored in quality, the company is expanding its products, standards, technologies, and services to support global public health.

關(guān)于揚(yáng)子江藥業(yè)集團(tuán)

長(zhǎng)江為魂，蒼生為念，奔騰不息的揚(yáng)子江，孕育滋養(yǎng)了以“求索進(jìn)取，護(hù)佑眾生”為使命的揚(yáng)子江藥業(yè)集團(tuán)。

創(chuàng)建于1971年的揚(yáng)子江藥業(yè)集團(tuán)，是科技部命名的全國(guó)首批創(chuàng)新型企業(yè)，總部位于江蘇省泰州市，現(xiàn)有員工19000余人，旗下子公司分布泰州、北京、上海、南京、廣州、成都、蘇州、常州等地。主要產(chǎn)品中西藥并舉，拓展生物藥、醫(yī)療器械、大健康業(yè)務(wù)，部分產(chǎn)品出口至全球40多個(gè)國(guó)家和地區(qū)。

堅(jiān)守質(zhì)量，揚(yáng)子江永恒不變的生命線。集團(tuán)踐行“高質(zhì) 惠民 創(chuàng)新 至善”的核心價(jià)值觀，視患者如親人，追求卓越品質(zhì)，致力向社會(huì)提供優(yōu)質(zhì)高效的藥品和健康服務(wù)。至今蟬聯(lián)全國(guó)醫(yī)藥行業(yè)質(zhì)量管理QC成果評(píng)比一等獎(jiǎng)總數(shù)“二十一連冠”，累計(jì)斬獲36項(xiàng)國(guó)際質(zhì)量管理小組會(huì)議（ICQCC）QC金獎(jiǎng)；2次榮獲“中國(guó)質(zhì)量獎(jiǎng)提名獎(jiǎng)”，3次奪得中國(guó)品牌價(jià)值評(píng)價(jià)醫(yī)藥健康板塊品牌價(jià)值、品牌強(qiáng)度“雙第一”。入選全國(guó)首批卓越級(jí)智能工廠。2021年，集團(tuán)榮獲全球三大質(zhì)量獎(jiǎng)之一的EFQM全球獎(jiǎng)；2025年4月，獲 EFQM RbE現(xiàn)場(chǎng)評(píng)審七星認(rèn)證；成為迄今國(guó)內(nèi)醫(yī)藥行業(yè)唯一獲此大獎(jiǎng)的制藥企業(yè)。

創(chuàng)新驅(qū)動(dòng)，揚(yáng)子江奔騰不息的原動(dòng)力。集團(tuán)把創(chuàng)新作為高質(zhì)量發(fā)展的戰(zhàn)略基點(diǎn)，實(shí)施中藥、化學(xué)藥、生物藥“三藥并舉”研發(fā)戰(zhàn)略，加快培育醫(yī)藥健康新質(zhì)生產(chǎn)力。建成4個(gè)國(guó)家級(jí)創(chuàng)新平臺(tái)；擁有40個(gè)獨(dú)家中藥品種；2021年，首個(gè)自主研發(fā)的1類化學(xué)創(chuàng)新藥注射用磷酸左奧硝唑酯二鈉獲批上市；2024年，1.1類中藥創(chuàng)新藥益氣通竅丸上市；2025年，1類化學(xué)創(chuàng)新藥鹽酸妥諾達(dá)非片上市獲批。至今累計(jì)180多個(gè)仿制藥品種通過(guò)或視同通過(guò)質(zhì)量和療效一致性評(píng)價(jià)。相繼榮獲3項(xiàng)國(guó)家科技進(jìn)步二等獎(jiǎng)；研究起草的5項(xiàng)中藥材質(zhì)量標(biāo)準(zhǔn)被錄入《歐洲藥典》。

責(zé)任同行，揚(yáng)子江護(hù)佑眾生勇?lián)?dāng)。集團(tuán)連續(xù)多年鼎力支持醫(yī)學(xué)科技進(jìn)步；第一時(shí)間馳援賑災(zāi)；發(fā)揮產(chǎn)業(yè)優(yōu)勢(shì)助力鄉(xiāng)村全面振興；熱心體育公益事業(yè)，廣泛支持健康促進(jìn)；捐資設(shè)立三大慈善基金會(huì)……揚(yáng)子江人在公益道路上向善而行。

展望未來(lái)，奮進(jìn)中的揚(yáng)子江藥業(yè)集團(tuán)，與時(shí)代同頻，與相關(guān)方攜手同行，踐行“健康營(yíng)銷 營(yíng)銷健康”雙健康戰(zhàn)略，沿著高質(zhì)量、可持續(xù)發(fā)展之路，推動(dòng)“藥、醫(yī)、養(yǎng)、食、游”融合發(fā)展，深耕大健康和國(guó)際化，貢獻(xiàn)全人類健康福祉，努力向“做中國(guó)領(lǐng)先、世界一流的醫(yī)藥健康產(chǎn)業(yè)集團(tuán)”的愿景邁進(jìn)。